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Abstract
Aims/hypothesis We analysed the genomic organisation of
miR-153, a microRNA embedded in genes that encode
two of the major type 1 diabetes autoantigens, islet-
associated protein (IA)-2 and IA-2β. We also identified
miR-153 target genes that correlated with IA-2β localisation
and function.
Methods A bioinformatics approach was used to identify
miR-153’s genomic organisation. To analyse the co-
regulation of miR-153 and IA-2β, quantitative PCR analysis
of miR-153 and Ia-2β (also known as Ptprn2) was
performed after a glucose stimulation assay in MIN6B cells
and isolated murine pancreatic islets, and also in wild-type
Ia-2 (also known as Ptprn), Ia-2β single knockout and Ia-
2/Ia-2β double knockout mouse brain and pancreatic islets.
Bioinformatics identification of miR-153 target genes and
validation via luciferase reporter assays, western blotting
and quantitative PCR were also carried out.
Results Two copies of miR-153, miR-153-1 and miR-153-
2, are localised in intron 19 of Ia-2 and Ia-2β, respectively.
In rodents, only miR-153-2 is conserved. We demonstrated
that expression of miR-153-2 and Ia-2β in rodents is
partially co-regulated as demonstrated by a strong reduc-
tion of miR-153 expression levels in Ia-2β knockout and
Ia-2/Ia-2β double knockout mice. miR-153 levels were
unaffected in Ia-2 knockout mice. In addition, glucose
stimulation, which increases Ia-2 and Ia-2β expression,
also significantly increased expression of miR-153. Sev-
eral predicted targets of miR-153 were reduced after
glucose stimulation in vitro, correlating with the increase
in miR-153 levels.
Conclusions/interpretation This study suggests the involve-
ment of miR-153, IA-2β and miR-153 target genes in a
regulatory network, which is potentially relevant to insulin
and neurotransmitter release.
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AKO Ia-2 single knockout
BKO Ia-2β single knockout
DCV Dense core vesicle
DKO Ia-2/Ia-2β double knockout
IA Islet-associated protein
IPA Ingenuity Pathway Analysis
NIH National Institutes of Health
miRNA MicroRNA
Pri Primary RNA transcript
PTP Protein tyrosine phosphatase
SCR Scrambled sequence
SNAP25 Synaptosomal-associated protein 25
SNCA Alpha-synuclein
TSS Transcription start site
UTR Untranslated region
VAMP2 Vesicle-associated membrane protein 2
Introduction
Islet-associated protein (IA) 2 and IA-2β are major
autoantigens in type 1 diabetes [1]. Based on sequence,
IA-2 and IA-2β, also known as ICA512 and phogrin, re-
spectively, are members of the transmembrane protein tyro-
sine phosphatase (PTP) family, but are enzymatically
inactive with standard PTP substrates because of two critical
amino acid substitutions in the PTP domain [2]. However,
recent studies have shown that IA-2β has low phos-
phatidylinositol phosphatase activity [3]. Both proteins con-
sist of an intracellular, transmembrane and luminal domain
and are produced in neuroendocrine cells throughout the
body (e.g. pancreatic islets, brain) [4–8]. Knockout mice
of the individual Ia-2 (also known as Ptprn) and Ia-2β (also
known as Ptprn2) genes and Ia-2/Ia-2β double knockout
(DKO) mice do not develop diabetes, but show abnormal
glucose tolerance, impaired insulin secretion and reduced
insulin content in beta cells [9–12]. Moreover, DKO mice
display defects in neurotransmitter release (dopamine, nor-
adrenaline [norepinephrine] and serotonin), resulting in be-
havioural and learning disturbances, seizures and reduced
lifespan [13]. These findings demonstrate that IA-2 and IA-
2β not only affect the secretion of insulin, but also that of
neurotransmitters, raising the possibility that defects in the
IA-2–IA-2β pathway might not only lead to glucose intol-
erance, but also to neurological disorders.
MicroRNAs (miRNAs) function as a rheostat of the
genome and proteome by controlling gene expression at
the post-transcriptional level [14]. These short (~21 to 23
nucleotides [nt]), conserved, non-coding RNA molecules
are transcribed from the genome as miRNA precursor mol-
ecules, which are processed to single stranded miRNA by a
series of ribonucleases. The mature miRNA is integrated
into the RNA-induced silencing complex (RISC) and binds
partial complementary mRNA sequences that mostly reside
in the 3′ untranslated region (UTR) of mRNA. Binding of
the miRNA to its target mRNA results in either translational
repression or mRNA destabilisation [15]. In mammals,
about one thousand conserved miRNAs have been identi-
fied and can be localised as either intragenic (intronic or
exonic) or intergenic [16]. Intragenic miRNAs can be tran-
scriptionally regulated by their own regulatory elements
and/or co-regulated with their host gene. A single miRNA
can influence the translation of several mRNA sequences at
once, potentially affecting parallel biological pathways.
Dysregulation of miRNA expression contributes to various
diseases, including cancer [17], and cardiovascular [18] and
neurodegenerative diseases [19].
Examination of the genomic sequence of IA-2 (also known
as PTPRN) and IA-2β (also known as PTPRN2) revealed that
two miRNAs, miR-153-1 and miR-153-2, are embedded in
these genes. Because of the importance of IA-2 and IA-2β in
type 1 diabetes, we investigated whether miR-153 expression
is co-regulated with IA-2 and IA-2β; we also determined
whether it might be involved in regulating target genes that
play a role in similar cellular functions to those affected by IA-
2 and IA-2β, such as secretion of neurotransmitters in the
brain and insulin release by beta cells in pancreas. This study
provides the first evidence of a miR-153–IA-2β–target gene
regulatory pathway and sets the stage for further investiga-
tions to obtain a greater mechanistic insight into this pathway.
Methods
Animal care and use Targeted disruption of the individual
Ia-2 and Ia-2β genes has been described previously [10–12,
20]. Because female Ia-2−/−/Ia-2β−/− mice are infertile, male
Ia-2−/−/Ia-2β−/− mice were bred to female Ia-2+/−/Ia-2β−/−
mice to generate Ia-2−/−/Ia-2β−/− (DKO) mice. Ia-2+/+/Ia-
2β+/+ wild-type mice served as controls. Animal studies were
conducted under protocols approved by the Institutional An-
imal Care and Use Committees of the USA at the National
Institutes of Health (NIH).
Reagents Cell culture reagents were purchased from
Invitrogen (Ghent, Belgium). Antibodies were derived from
the following sources: mouse anti-β-actin (A5441; Sigma-
Aldrich [Diegem, Belgium]), mouse anti-alpha-synuclein
(SNCA) (610787; BD-Biosciences [Erembodegem, Bel-
gium]), mouse anti-parkin (PARK2) (MAB5512; Millipore
[Overijsse, Belgium]), rabbit anti-synaptosomal-associated
protein 25 (SNAP25) (AB1762; Millipore) and mouse anti-
bassoon (monoclonal antibody SAP7F407; Enzo Life
Sciences, [Antwerpen, Belgium]). Total RNA from mouse
pancreas, heart and brain was purchased from Biochain
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(Kampenhout, Belgium). Total RNA and miRNA from
wild-type and DKO mouse islets were extracted using a
kit (miRNeasy Mini kit; Qiagen [Antwerpen, Belgium])
according to the manufacturer’s protocols.
Cell lines MIN6B mouse insulinoma cell line (ATCC,
Molsheim, France) was cultured at 37°C in 95% air and 5%
CO2 in DMEM supplemented with 15% vol./vol. heat-
inactivated fetal bovine serum, 2 mmol/l L-glutamine,
100 U/ml penicillin and 0.1 mg/ml streptomycin. The human
neuroblastoma SH-SY5Y cell line (ATCC) was cultured in
DMEM/F12 medium supplemented with 10% vol./vol. fetal
bovine serum, 100 U/ml penicillin and 100 μg/ml streptomy-
cin; the culture process was at 37°C in 95% air and 5% CO2.
Glucose-stimulated gene expression assay in fresh mouse
islets Islets from 3- to 4-month-old sex-matched mice were
isolated as previously described [21], with slight modifica-
tions according to the manufacturer’s protocol for Collage-
nase P (Roche, Indianapolis, IN, USA), and stimulated with
various concentrations of glucose, followed by RNA extrac-
tion and quantitative PCR analysis. See electronic supple-
mentary material (ESM) Methods for further details.
Glucose-stimulated gene expression assay in MIN6B
cells MIN6B cells were stimulated with various concentra-
tions of glucose, followed by RNA extraction and quantita-
tive PCR analysis. See ESM Methods for further details.
Quantitative RT-PCR (mRNA) Total RNA was extracted
using a kit (mirVana Paris kit; Applied Biosystems [Ghent,
Belgium]) and following the manufacturer’s instructions.
RT-PCR was performed with a high-capacity cDNA reverse
transcription kit (Applied Biosystems) according to the
manufacturer’s instructions; for quantitative PCR we used
the Taqman gene expression assay (Applied Biosystems) for
Ia-2, Ia-2β, primary RNA transcript (pri) pri-miR-153
(Mm03306386_pri), Snca, Syt1, Syt4, Bsn, Pclo, Vamp2,
Snap25, Gapdh, Tbp and β-actin according to the manufac-
turer’s instructions and using a LightCycler 480 Real-Time
PCR System (Roche, Basel, Switzerland).
Quantitative RT-PCR (miRNA) Total RNA was extracted
using a kit (mirVana Paris kit; Applied Biosystems) and
following the manufacturer’s instructions. Each RT-PCR
reaction was performed in triplicate. The Taqman miRNA
reverse transcription kit (Applied Biosystems) and the
Taqman Universal PCR master mix (Applied Biosystems)
were used according to the manufacturers’ instructions. The
quantitative PCR procedures were carried out following the
instructions provided with the Taqman miRNA assays (Ap-
plied Biosystems). The following miRNA assay was used:
mmu-miR-153 (Applied Biosystems). Relative miR-153
expression was calculated by using the comparative cycle
threshold method and normalised to the following reference
genes: RNU19 (also known as Snora74a), Sno135 (also
known as Snord65) and miR-16.
Bioinformatics identification of potential miR-153 targets
involved in neurotransmitter and insulin release Analysis
of co-production of IA-2β and predicted miR-153 targets
(predicted by Targetscan www.targetscan.org release 6.2,
accessed June 2012; 629 top predicted conserved targets)
in brain and pancreas was performed by searching the
literature. Overlap of IA-2β and miR-153 target gene ex-
pression was further validated using the following online
gene expression databases: BIOGPS (http://biogps.gnf.org,
accessed Sept 2012), the type 1 diabetes database (T1Dbase)
(www.t1dbase.org, accessed Sept 2012) and the Allan brain
atlas (www.brain-map.org/, accessed Sept 2012) (data not
shown). Targets that met these criteria were used for further
analysis to determine possible protein×protein interactions
and gene–function relationships between the predicted targets
using Ingenuity Pathways Analysis (IPA) 9.0 (Ingenuity
Systems, www.ingenuity.com, accessed Sept 2010).
Protein extraction and western blot analysis Cultured cells
were rinsed with cold PBS and lysed in the cell disruption
buffer from the mirVANA Paris kit (Applied Biosystems).
Note that with this extraction procedure, co-isolation of
proteins and high-quality RNA (including the small RNA
species) from the same sample is possible, allowing direct
comparative measurements (of miRNAs, mRNA and pro-
tein) within a given tissue or cells. This protocol was used to
extract RNA and proteins from SH-SY5Y cells, and from
adult wild-type, Ia-2 single knockout (AKO), Ia-2β single
knockout (BKO) and DKO mouse brains. Proteins were
analysed by western blotting according to standard proce-
dures. See ESM Methods for further details.
Transfections, DNA cloning and luciferase assay MIN6B
and SH-SY5Y cells were transfected using a transfection
reagent (HiPerFect; Qiagen) or Lipofectamine 2000
(Invitrogen) according to the manufacturers’ instructions and
further processed for quantitative PCR analysis or luciferase
reporter assays. See ESM Methods for further details.
Results
Localisation and co-regulation of miR-153 and IA-2/IA-2β
genes Genomic localisation of many mammalian miRNA
transcription units has been determined previously [22].
Using these data and the University of California Santa Cruz
(UCSC) genome browser (http://genome.ucsc.edu/cgi-bin/
hgTracks, accessed Sept 2012), we determined that two
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copies of the miR-153 small non-coding miRNAs exist in
the human genome. In humans, miR-153-1 is localised
at a highly conserved region in intron 19 of IA-2 on
chromosome 2 (chr2:219862589-219882387) (Fig. 1a).
miR-153-2 is localised at a highly conserved intronic region
between exon 19 and 20 of IA-2β on chromosome 7
(chr7:157059789-157059875) (Fig. 1a). Next, we used
ClustalW multiple alignment software (www.genome.jp/
tools/clustalw/) to determine whether miR-153-1 and miR-
153-2 are evolutionarily conserved (Fig. 1b). We found that
although miR-153-2 is evolutionarily highly conserved,
miR-153-1 is more divergent. In particular, in rodents
(mouse, rat), polymorphisms are localised within the seed
sequence of miR-153-1. This makes it very unlikely that
functional miR-153 is generated from the miR-153-1 tran-
scription unit in rodents. This was validated by performing a
predicted hybridisation analysis using the RNAhybrid algo-
rithm [23] and SNCA 3′ UTR as a confirmed miR-153 target
[24] (ESM Fig. 1). These data indicate that, based on the
strong evolutionary conservation of miR-153-2 within the
intron of the IA-2β gene, miR-153-2 and IA-2β might be
functionally connected and co-regulated.
To investigate whether expression of miR-153-2 and IA-
2β are co-regulated, we determined whether the IA-2β
mRNA and the pri-miR-153 transcript are generated from
the same or separate heterogeneous nuclear (hn)RNA tran-
scripts. We therefore first analysed the expression of mir153
in brain material of wild-type, AKO, BKO and DKO mice.
AKO and BKO mice were generated previously, resulting in
a complete loss of Ia-2 and Ia-2β mRNA expression and
protein production [10, 12]. The knockout strategy does not
target the intron in which miR-153-2 is located. Quantitative
PCR measurements showed that miR-153 expression was
reduced in BKO and DKO, but not in wild-type or AKO
mouse brain material after normalisation to three independent
small non-coding RNA controls (miR-16 [also known as
Gde1], RNU19 [also known as Snora74a], Sno135; only re-
sults for the latter are shown) (Fig. 2a). To rule out the possi-
bility that the observed remaining miR-153 was generated by
cross-hybridisation of the oligonucleotides with the miR-153-1
sequences in the Ia-2 locus, we analysed expression of the pri-
miR-153-2 product, which only results in the amplification of
the miR-153-2, but not of the miR-153-1 product. We showed
that pri-miR-153 expression was reduced to the same extent as
that of mature miR-153 in BKO andDKO, but not in wild-type
and AKO mouse brain RNA (Fig. 2b). Interestingly, pri-miR-
153 expression was reduced to almost undetectable levels in
isolated DKO islets compared with wild-type (Fig. 2c).
Next, we analysed mirR-153 expression in mouse
MIN6B cells and isolated mouse pancreatic islets after glu-
cose stimulation (Fig. 2d,e). We detected a significant in-
crease in the expression of miR-153, Ia-2 and Ia-2β after
glucose stimulation of MIN6B cells at 25 mmol/l glucose
compared with 5 mmol/l glucose (Fig. 2d). Finally, increasing
Fig. 1 Genomic organisation of miR-153 transcription unit. (a)
Schematic representation of the IA-2 and IA-2β genomic loci (not
to scale). The locations of miR-153-1 and miR-153-2 are indicat-
ed (between exon 19 and exon 20). The IA-2 gene in humans and
mice extends over 20 kb and consists of 23 exons. The genomic
structure of IA-2β in humans and mice consists of 23 exons and
spans approximately 1,000 and 800 kb, respectively. (b) Evolu-
tionary conservation of miR-153-1 and miR-153-2 sequences as
determined by ClustalW alignment. Seed sequences are
underlined. Black or grey shading indicates conserved or non-
conserved residues, respectively. X. tropicalis, Xenopus tropicalis
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glucose levels from 3.3 to 16.7 mmol/l dramatically increased
miR-153, Ia-2 and Ia-2β expression in cultured isolated
mouse islets (Fig. 2e). These studies show that miR-153, Ia-
2 and Ia-2β expression is increased after glucose stimulation
in MIN6B cells and isolated mouse pancreatic islets.
These results also show that whereas miR-153 expression
was almost completely lost in DKO islets (Fig. 2c), miR-153
levels in DKO brain were still detectable at about 50%
of the levels found in wild-type mouse brain (Fig. 2b). This
might indicate that in addition to miR-153 being generated
from a transcript and transcription start site (TSS) shared
with the host gene Ia-2β, an alternative tissue-specific
transcript and TSS for miR-153 might exist independently
of its host gene Ia-2β. Moreover, the targeted Ia-2β allele
was generated by deleting its promoter region [10]. Thus,
loss of the Ia-2β promoter rules out the possibility that
any remaining miR-153 expression is generated from shared
regulatory elements in the promoter region of its host gene,
Ia-2β. We performed an in silico analysis of putative
miR-153-2 TSSs in humans, using a miRStart database search
[25]. A putative miR153-2 TSS was identified at 38,909 bp
from the start of the miR-153 precursor (ESM Fig. 2). Further
experimental evidence, outside the scope of the current study,
would be required to determine whether this is a conserved
and tissue-specific miR-153 TSS.
Bioinformatics identification of potential miR-153 targets
involved in neurotransmitter and insulin release Many
potential miR-153 targets can be determined by various
miRNA target-prediction software programs (data not
shown). However, only a few miR-153 targets have been
experimentally validated [24, 26–31]. Although it is gener-
ally accepted that miRNA–mRNA co-expression leads to
inhibition of target protein levels [15], several reports indi-
cate that this correlation is less apparent in postnatal brain,
where miRNA expression can be associated with the pres-
ence rather than absence of target protein expression [32,
33]. Furthermore, it has previously been shown that intronic
miRNAs can regulate the expression of their target genes,
which can play a role in the same functional regulatory
pathway as the host gene in which the miRNA is located
[34, 35]. Based on these findings and our observation that
miR-153-2 and IA-2β expression are co-regulated, we can
narrow down the list of candidate miR-153 targets based on
its co-regulation with IA-2β expression. Predicted targets of
miR-153 and potential protein regulatory networks regulat-
ed by miR-153 have previously been identified [24]. Using
bioinformatics analysis (see Methods), we set out to refine
this list of potential miR-153 targets as defined by correla-
tion with IA-2β expression patterns (brain and pancreas) and
IA-2β function (i.e. synaptic vesicle and dense core vesicle
[DCV] release). From this analysis we extracted target genes
that are highly associated with IA-2β expression and func-
tion (ESM Table 1). Next, we used IPA software to deter-
mine gene–function relationships (Table 1) and potential
interactions (Fig. 3a) between IA-2β, miR-153 and the
Fig. 2 Co-regulation of miR153 and Ia-2β expression. (a) Quantita-
tive PCR analysis of miR-153 mRNA expression in wild-type (WT),
AKO, BKO and DKO mouse brain. Relative expression (fold) was
calculated using the relative cycle threshold quantification method
(2−ΔΔCt ) and normalised to Sno135; WT n=6, AKO n=4, BKO n=4,
DKO n=6. (b) Quantitative PCR analysis of pri-miR-153 mRNA
expression in mice as above (a). Relative expression (fold) was calcu-
lated as above (a) and normalised to Tbp; WT n=6, AKO n=4, BKO
n=4, DKO n=6. (c) Quantitative PCR analysis of pri-miR-153 mRNA
expression in wild-type and DKO mouse pancreatic islets. Relative
expression (fold) was calculated as above (a) and normalised to Tbp;
WT n=6, DKO n=6. (d) Quantitative PCR analysis of Ia-2, Ia-2β and
miR-153 transcript levels in cultures of MIN6B cells at 5 mmol/l
(black bars) and 25 mmol/l (white bars) glucose stimulation. Relative
expression (fold) was calculated as above (a) and normalised to
β-actin. n=3. (e) Quantitative PCR analysis of Ia-2, Ia-2β and miR-153
transcript levels in pancreatic islets from adult wild-type (C57BL/6)
mice upon stimulation with 3.3 mmol/l (black bars) and 16.7 mmol/l
(white bars) glucose. Relative expression (fold) was calculated as
above (a) and normalised to β-actin; n=6. Experiments (a–e) were
performed in triplicate and significance determined by Mann–Whitney
U test, *p<0.05 and **p<0.01
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Relevant biological function p value Moleculesa
Fusion of synaptic vesicles 3.40×10–12 BSN, SNAP25, SYT1, VAMP2
Secretion of neurotransmitter 4.21×10–12 PTPRN2, SNAP25, SNCA, SYT1, SYT4, VAMP2
Transport of synaptic vesicles 5.63×10–12 PCLO, SNCA, SYT1, SYT4, VAMP2
Exocytosis 2.48×10–11 PCLO, SNAP25, SNCA, SYT1, SYT4, VAMP2
Exocytosis by cells 2.43×10–10 PCLO, SNAP25, SNCA, SYT1, VAMP2
Release of neurotransmitter 5.64×10–10 PCLO, SNAP25, SNCA, SYT1, SYT4, VAMP2
Excitatory postsynaptic potential 4.20×10–8 SNAP25, SNCA, SYT1, VAMP2
Presence of fusion pores 1.13×10–7 SYT1, SYT4
Quantity of synaptic vesicles 1.82×10–7 PCLO, PTPRN2, SNCA
Miniature excitatory postsynaptic
currents
3.00×10−7 SNAP25, SYT1, VAMP2
Synthesis of neurotransmitter 6.70×10−7 SNAP25, SNCA, SYT1
Exocytosis of vesicles 7.10×10−7 SNAP25, SYT1, VAMP2
Flux of noradrenaline 2.38×10−6 SYT1, SYT4
Synaptic transmission 6.55×10−6 BSN, SNAP25, SNCA, SYT1
Exocytosis of synaptic vesicles 3.96×10−5 SYT1, VAMP2
Secretion of dopamine 4.58×10−5 PTPRN2, SNCA
Secretion of L-glutamic acid 5.95×10−5 PTPRN2, SNCA
Exocytosis of granules 7.09×10−5 SYT4, VAMP2
Endocytosis 1.64×10−4 SNAP25, SNCA, SYT1
Fusion of cellular membrane 1.92×10−4 SYT4, VAMP2
Fig. 3 miR-153 target gene prediction analysis. (a) Predicted
protein×protein interactions using IPA 9.0. Various points of interac-
tion between the candidate miR-153 targets are shown. The arrow from
protein tyrosine phosphatase, receptor type, N polypeptide 2
(PTPRN2, also known as IA-2β) to miR-153 indicates that PTPRN2
affects the abundance of miR-153. Red lines with a short line at the end
indicate an inhibitory effect of miRNA target gene interaction. Lines
between two proteins indicate that only binding was detected. Blue
arrows indicate the direction of protein×protein interaction. BSN,
bassoon; PCLO, piccolo; SYT, synaptotagmin. (b) Expression of
predicted targets as indicated was determined by quantitative PCR on
adult wild-type mouse total RNA from pancreas (black bars), heart
(grey bars) and brain (white bars). (c) Expression of pri-miR-153 was
determined by quantitative PCR in adult wild-type (C57BL/6) mouse
total RNA from pancreas (black bar), heart (grey bar) and brain (white
bar). (b,c) Relative expression (fold) of miR-153 was calculated using
the relative quantification method, taking mouse pancreas levels as
calibrator, i.e. onefold. All data were normalised to Tbp in three
independent experiments (n=4)
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selected human candidate miR-153 target genes. We also
showed that the predicted target genes and miR-153 are
expressed in pancreas and brain as determined by quantita-
tive PCR (Fig. 3b,c). Our data support a significant associ-
ation of miR-153 and its target genes with vesicle exocytosis
[24, 36–38]. Based on these findings, the identified candi-
dates are very likely to be regulated by miR-153.
Analysis of regulation of predicted miR-153 target genes in
vivo and in vitro Based on our data showing that miR-153
expression is significantly reduced in mouse pancreatic is-
lets (Fig. 2c) and to a lesser extent in brains from DKO mice
(Fig. 2b), we hypothesised that the expression of predicted
target genes would be increased in DKO islets and brains.
To test this, we examined the mRNA expression of predict-
ed miR-153 targets in DKO islets and BKO mouse brains
(Fig. 4a,b). In islets we found a significant increase in Pclo,
Snap25 and Vamp2 expression (Fig. 4a), whereas only Bsn
expression was significantly increased in DKO mouse brain
(Fig. 4b). Although most other targets followed a trend
towards increased expression, they did not show statistically
significant changes. Next, based on our data showing that
miR-153 expression was induced after glucose stimulation
in MIN6B cells (Fig. 2d), we hypothesised that the expres-
sion of predicted target genes would be reduced after glu-
cose stimulation if they are directly regulated by miR-153
action. To analyse this possibility, we used quantitative PCR
to investigate target gene expression in glucose-stimulated
MIN6B cells (Fig. 4c). Here we found that Bsn expression
was significantly reduced (Fig. 4c), whereas most other
targets, although showing a trend towards reduced expres-
sion, did not change significantly. Subsequently, to deter-
mine whether overexpression of miR-153 in mouse MIN6B
or in human neuroblastoma SHSY5Y cells leads to reduced
target gene expression, we transfected these cells either with
miR-153 pre-miR precursor or a scrambled control precur-
sor (SCR) (both at 50 nmol/l final concentration) and
analysed target gene expression at 48 h after transfection.
miR-153 expression was analysed by quantitative PCR
analysis to determine the extent of miR-153 overexpression
Fig. 4 miR-153 regulation of SNCA expression in vitro and expression
of miR-153 targets after glucose stimulation and in Ia-2β knockout
mice. (a) Gene expression analysis of predicted miR-153 target genes
as determined by quantitative PCR in pancreatic islets of wild-type
(black bars) and Ia-2/Ia-2β knockout (white bars) mice or (b) in brains
of wild-type (black bars) and Ia-2β knockout (white bars) mice. The
relative expression (as percentage of wild-type) of miR-153 targets was
calculated using the relative quantification method (taking the level of
wild-type for each target gene as calibrator, i.e. set at 100%) and
normalised to Tbp. (c) Gene expression analysis as above (a,b) in
MIN6B cells in response to 5 mmol/l (black bars) or 25 mmol/l (white
bars) glucose stimulation. The relative expression of miR-153 targets
(as percentage of 5 mmol/l glucose treatment) was calculated using the
relative quantification method (with 5 mmol/l glucose for each target
gene as calibrator, i.e. set at one) and normalised to Tbp. (d) Gene
expression analysis as above (a,b) in MIN6B cells or (e) SH-SY5Y
cells after induction of miR-153 precursor or SCR overexpression. The
relative expression of miR-153 targets (as percentage of SCR treat-
ment) was calculated using the relative quantification method and
normalised to Tbp. (a–e) Error bars represent SEM; n>3 independent
duplicate experiments. Significance was determined using the Mann–
Whitney U test, *p<0.05 and **p<0.01. (f) Western blot analysis of
endogenous bassoon, SNAP25, alpha-synuclein (SNCA), parkin and
β-actin in SH-SY5Y cells treated with 50 nmol/l (final concentration)
of miR-153 or SCR
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(ESM Fig. 3). We found significantly reduced expression of
Bsn and Syt4 in mouse MIN6B cells (Fig. 4d), and signifi-
cantly reduced BSN, SNAP25, SNCA and SYT4 expression
in human SH-SY5Y cells (Fig. 4e). Next, we asked whether
miR-153 can regulate endogenous protein levels of these
predicted targets in SH-SY5Y cells. We used protein ex-
tracts from the same transfected cells used for the quantita-
tive PCR analysis (Fig. 4e). We analysed the abundance of
bassoon, SNAP25 and SNCA in SH-SY5Y cells, and
showed that miR-153 overabundance downregulated bas-
soon abundance by 83%, SNAP25 by 43% and SNCA by
78% compared with scrambled control transfected cells
(Fig. 4f). Protein levels of parkin and the housekeeping gene
β-actin, which do not have any predicted miR153 seed se-
quences, remained unaffected by miR-153 overabundance.
Finally, to determine whether the predicted targets can be
directly regulated by miR-153, we selected SNCA, bassoon
and piccolo for further analysis. SNCA expression has been
shown to be regulated by miR-153 [24], and both SNCA
and IA-2β localise to secretory granules in beta cells, as
well as to synaptic vesicles in neurons [13, 39]. We con-
firmed that SNCA expression is regulated by miR-153 in
vitro (Fig. 4e,f). Regulation of bassoon and piccolo levels
by miR-153 has not been investigated. The human SNCA,
BSN and PCLO 3′ UTRs (wild-type) or 3′ UTR with a
mutated miR-153 seed sequences (seed mutant) were cloned
after the stop codon of Firefly luciferase under control of the
human thymidine kinase promoter in the pGL3 expression
construct (ESM Fig. 4) and co-transfected in SH-SY5Y cells
with miR-153 or a negative control SCR (pre-miR precur-
sor; 50 nmol/l; Ambion [Ghent, Belgium]). Co-transfection
of miR-153 and luciferase constructs produced 35%, 80%
and 40% reductions of Firefly luciferase activity in lucifer-
ase reporter constructs containing the 3′ UTRs of SNCA,
BSN, and PCLO, respectively (Fig. 5). Mutation of the
miR-153 seed sequence (seed mutant) abolished the inhib-
itory effect of miR-153 on luciferase activity in luciferase
reporters of SNCA,and BSN. The human PCLO 3′ UTR
contains two miR-153-binding sites (ESM Fig. 4). Only
mutation of the B seed sequence abolished the inhibitory
effect of miR-153 on the PCLO 3′ UTR luciferase reporter.
These data show that miR-153 directly interacts with pre-
dicted seed sequences in SNCA, BSN and PCLO 3′ UTRs to
inhibit translation of the luciferase reporter protein levels.
These data indicate that changes in miR-153 abundance
in various settings can result in significant changes of pre-
dicted target gene expression.
Discussion
This study describes the localisation of miR-153-1 and miR-
153-2 in introns of the human IA-2 and IA-2β genomic loci,
respectively. We show that only miR-153-2 is evolutionarily
conserved and partly co-regulated with IA-2β expression, as
loss of Ia-2β expression in BKO mice results in a strong
reduction of miR-153 expression. We identified several
potential miR-153 targets that correlate with IA-2β expres-
sion and function. We found significant changes in mRNA
expression of several predicted target genes after glucose
stimulation of MIN6B cells, as well as in isolated mouse
pancreatic islets, where endogenous miR-153 levels are
increased, and in BKO mouse brain and isolated islets,
which have reduced miR-153 levels. Moreover, significant
reductions of bassoon, SNAP25 and SNCA abundance in
SH-SY5Y cells was found upon overproduction of miR-153
(Fig. 4f). It should be noted that in vivo miRNAs mainly
function as rheostats or act via neutral repression, rather
than being a binary off-switch to dampen protein output
[15, 40].
The first point that arises from our study is that although
in BKO mice mRNA expression of Ia-2β is completely lost
[10], reduced levels of miR-153 can still be detected in BKO
and DKO brain, whereas miR-153 expression in DKO islets
is almost completely lost (Fig. 2b, c). Interestingly, the effect
of loss of miR-153 on predicted target gene expression
appears to be more pronounced in isolated mouse knockout
islets than in mouse knockout brains (Fig. 4a,b), correlating
with the stronger reduction of miR-153 levels in knockout
islets than in knockout brain. Moreover, the targeted Ia-2β
allele was generated by deleting its promoter region [10].
Thus, loss of the Ia-2β promoter rules out the possibility that
Fig. 5 Luciferase reporter analysis of predicted miR-153 targets.
Luciferase and Renilla luciferase constructs were transfected into SH-
SY5Y cells with the miR-153 (black bars) or SCR (grey bars)
oligonucleotides at a final concentration of 50 nmol/l. Wild-type or
seed mutant SNCA, BSN and PCLO 3′ UTR construct signals (see ESM
Fig. 4, luciferase activity normalised to Renilla) are shown as a
percentage of the signal in control cells transfected with SCR. Error
bars represent SEM; n>3 independent triplicate experiments. Signifi-
cance was determined using Mann–Whitney U test, *p<0.05
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any remaining miR-153 expression that was detected in
BKO and DKO mice was generated from shared regulatory
elements in the promoter region of its host gene, Ia-2β, thus
predicting the presence of an independent and tissue-
specific miR-153 promoter region. Using miRStart software
[25], we were able to detect putative transcription regulatory
elements for miR-153-2 (ESM Fig. 2). Another study has
also predicted a promoter region for miR-153-2 indepen-
dently of the Ia-2β TSS [41]. However, a recent study
failed to find evidence that human miR-153-2 has a
classical TSS, but instead contains a CpG island and
transcription factor binding sites that could initiate tran-
scription [42]. Interestingly, demethylation of methylated
cytosines in two identified miR-153-2 CpG islands in-
creases miR-153 expression [26]. Based on these studies
and our findings, it is clear that miR-153-2 transcription
unit can be regulated independently of Ia-2β expression
in a tissue-specific manner, but more detailed studies will
be required to elucidate the exact transcriptional regula-
tion of miR-153-2 expression.
Based on our present findings, earlier studies [9–13] that
described the use of material from BKO or DKO mice
should be judged with some caution, as it is possible that
(some of) the observed results could have been caused by
loss of miR-153 expression and potential upregulated
expression of their targets. This issue probably needs
to be considered in general for other studies that have
generated targeted deletion in genes that contain intragenic
miRNAs.
The present study points to the existence of a potential
miR-153–IA-2β–target gene pathway, which is involved in
vesicle release in brain and pancreas. Indeed, it has already
been shown that IA-2β localises to synaptic vesicles and
that loss of IA-2β results in decreased dopamine release in
PC12 cells [13, 43]. Furthermore, DKO mice display defects
in neurotransmitter release (dopamine, noradrenaline and
5-hydroxytryptamine (5-HT)) [13]. Various targets of miR-
153 have the same localisation and function in the same
pathways as IA-2β. For example, both SNCA and IA-2β
localise to DCVs of beta cells, where loss of SNCA in-
creases insulin release and loss of IA-2β decreases insulin
release [9, 39]. In addition, SNCA is a presynaptic protein
that regulates synaptic vesicle dynamics and trafficking, and
physically interacts with at least three other predicted miR-
153 target genes, i.e. Vamp2, Pclo and Snap25, to stimulate
soluble n-ethyl maleimide sensitive factor (NSF) attachment
protein receptor (SNARE) complex assembly [44]. Interest-
ingly, mild overabundance of SNCA in mice resulted in a
marked reduction of neurotransmitter release [45], similar to
the phenotype observed in BKO mice [13]. Moreover, it has
been shown that miR-153 expression is reduced in synapto-
somes in comparison with the expression in total brain [32,
46, 47]. Finally, miR-153-1 has been associated with one of
the type 1 diabetes mellitus loci (IDDM13), indicating
that miR-153 may be a susceptibility candidate for
human type 1 diabetes [48]. Taken together, the pres-
ence of miR-153-2 in the Ia-2β gene locus could be
part of a feedback loop including miR-153 targets, and
possibly regulating release of neurotransmitters at syn-
apses and insulin secretion by beta cells. This possibil-
ity underscores the importance of the IA-2β–miR-153–
target gene pathway in brain and pancreas, and sets the
stage for further investigations to obtain a greater mech-
anistic insight into this pathway.
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